BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Must-Have Cooking Machine in Your Kitchen - 25 Side interests That Work on Psychological wellness
- 3As world leaders enter climate talks, people in poverty have the most at stake
- 4Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- 5The Best Computer games for Multiplayer Fun
- Outside Lovers' Decision: Favored Climbing Rucksacks
- Investigating the Financial History of the World: A Succinct Outline
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
- Select Your Cherished Fish
- Top Breakfast Food: What's Your Morning Enjoyment?
- Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- Elite Execution Wall televisions for Film Darlings
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Kids
- 'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
